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Abstract
Although high dose n-3 PUFA supplementation reduces exercise- and hyperpnoea-induced bronchoconstriction (EIB/HIB), there are
concurrent issues with cost, compliance and gastrointestinal discomfort. It is thus pertinent to establish the efﬁcacy of lower n-3 PUFA doses.
Eight male adults with asthma and HIB and eight controls without asthma were randomly supplemented with two n-3 PUFA doses (6·2 g/d
(3·7 g EPA and 2·5 g DHA) and 3·1 g/d (1·8 g EPA and 1·3 g DHA)) and a placebo, each for 21 d followed by 14 d washout. A eucapnic
voluntary hyperpnoea (EVH) challenge was performed before and after treatments. Outcome measures remained unchanged in the control
group. In the HIB group, the peak fall in forced expiratory volume in 1 s (FEV1) after EVH at day 0 (−1005 (SD 520)ml, −30 (SD 18)%) was
unchanged after placebo. The peak fall in FEV1 was similarly reduced from day 0 to day 21 of 6·2 g/d n-3 PUFA (−1000 (SD 460)ml,
−29 (SD 17)% v. −690 (SD 460)ml, −20 (SD 15)%) and 3·1 g/d n-3 PUFA (−970 (SD 480)ml, −28 (SD 18)% v. −700 (SD 420)ml, −21 (SD 15)%)
(P< 0·001). Baseline fraction of exhaled nitric oxide was reduced by 24% (P= 0·020) and 31% (P= 0·018) after 6·2 and 3·1 g/d n-3 PUFA,
respectively. Peak increases in 9α, 11β PGF2 after EVH were reduced by 65% (P= 0·009) and 56% (P= 0·041) after 6·2 and 3·1 g/d n-3 PUFA,
respectively. In conclusion, 3·1 g/d n-3 PUFA supplementation attenuated HIB and markers of airway inﬂammation to a similar extent as a
higher dose. Lower doses of n-3 PUFA thus represent a potentially beneﬁcial adjunct treatment for adults with asthma and EIB.
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Exercise-induced bronchoconstriction (EIB) is a prominent
asthma phenotype affecting an estimated 90% of asthma
patients and up to 50% of elite athlete populations(1). EIB is
characterised by transient airway narrowing during and/or
after exercise(2) and is ascribed to airway drying leading to
degranulation of inﬂammatory cells and release of inﬂammatory
mediators(3,4). Inhaled corticosteroids and short- and long-
acting β2-agonists are effective therapies, but they are not
curative and do not modify disease progression(5). Furthermore,
inhaled corticosteroids adherence is notoriously poor and may
have undesirable side effects, whereas chronic β2-agonist use
results in tolerance(5,6). Development of therapies that modulate
asthma immunopathology without adverse side effects is
therefore desirable.
One potential candidate therapy involves the long-chain
n-3 PUFA, EPA and DHA(7). Dietary supplementation of n-3
PUFA increases cell membrane EPA and DHA content and
reduces n-6 arachidonic acid content(8). This subsequently
reduces the synthesis of the pro-inﬂammatory arachidonic
acid-derived eicosanoids cysteinyl leukotrienes and PG. EPA
and DHA may also increase synthesis of resolvin and protectin
compounds through the cyclo-oxygenase and lipoxygenase
pathways which are involved in the resolution of inﬂammation.
These mechanisms are thought to be central to the
well-established anti-inﬂammatory effects of n-3 PUFA(8), which
provide a rationale for the use of n-3 PUFA in asthma(7). To
date, however, the role of EPA and DHA in the management of
asthma and EIB remains uncertain(9–14). Early research showed
Abbreviations: EIB, exercise-induced bronchoconstriction; EVH, eucapnic voluntary hyperpnoea; FENO, fraction of exhaled nitric oxide; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; HIB, hyperpnoea-induced bronchoconstriction; ppb, parts per billion.
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that supplementation of 5·4 g/d n-3 PUFA (3·2 g/d EPA and
2·2 g/d DHA) for 10 weeks in adults with asthma reduced
leukotriene generation and neutrophil chemotactic responsive-
ness, but did not reduce bronchoconstriction after cycling
exercise and a histamine challenge(9). Similarly, supplementation
of 6·0 g/d n-3 PUFA (4·0g/d EPA and 2·0 g/d DHA) for 3 weeks
in adults with asthma did not attenuate bronchoconstriction
or markers of airway inﬂammation in response to a mannitol
challenge test(12). Conversely, supplementation of 5·4 g/d n-3
PUFA (3·2 g/d EPA and 2·2 g/d DHA) for 3 weeks in elite
athletes(10) and physically active asthmatic males(11,15) abolished
EIB. Subsequent studies showed that supplementation of n-3
PUFA (3·2 g/d EPA and 2·0 g/d DHA) reduced bronchoconstric-
tion and markers of airway inﬂammation after eucapnic
voluntary hyperpnoea (EVH)(16) and that n-3 PUFA 3·2g/d EPA
and 2·0 g/d DHA) was as effective as a leukotriene modiﬁer(17).
Given the lack of reported risk in taking n-3 PUFA, the
American Thoracic Society/European Respiratory Society
(ATS/ERS) guidelines suggest that the latter studies offer some
support for the consumption of n-3 PUFA by interested individuals
with EIB(10,11,17). In contrast however, recent practice parameter(14)
cautions the recommendation for n-3 PUFA use in EIB based on
more recent ﬁndings(12,18). When considering the practicalities
associated with n-3 PUFA supplementation for asthma man-
agement, previous studies have used doses of 5·2–6·0 g/d. Such
doses require individuals to ingest between eight and twenty
capsules of commercial ﬁsh oil daily, which has implications
for cost, compliance and gastrointestinal discomfort(19,20). In a
single-blind study an alternative ﬂavoured beverage delivery
was investigated (3·0 g/d EPA, 3·0 g/d DHA and 30 µg of vitamin
D3) but failed to show any attenuation in hyperpnoea-induced
bronchoconstriction (HIB) or markers of airway inﬂammation
(fraction of exhaled nitric oxide (FENO), urinary 9α, 11β PGF2
and cysteinyl leukotriene E4)(18). However, no measure of
compliance to the treatment was made and participants inclu-
ded had mild asthma or did not have a physician diagnosis of
asthma. It is therefore pertinent to establish if lower doses of n-3
PUFA are effective in reducing EIB. With respect to the simu-
lation of EIB under laboratory conditions, an EVH challenge
causes a highly reproducible HIB (a surrogate for EIB) in adults
with asthma(21) which makes this an attractive challenge test to
evaluate the effects of n-3 PUFA treatments on airway hyper-
responsiveness. Thus, the aim of the current study was to
compare the effects of a 6·2 g/d n-3 PUFA dose with a half dose
of 3·1 g/d n-3 PUFA on HIB and markers of airway inﬂamma-
tion in adults with asthma. Provisional data from the study was
previously part published in abstract form(22).
Methods
Participants
In all, sixteen non-smoking, recreationally active men (com-
pleting ≥6 h of endurance exercise per week) provided written,
informed consent to participate in the study (Table 1). Eight
participants formed a HIB group and eight formed a control
group. Inclusion criteria for the HIB group were: physician
diagnosis of asthma, a baseline forced expiratory volume in 1 s
(FEV1) >65% of predicted
(23) and a ≥10% fall in FEV1 following
initial EVH screening(24,25). The HIB group were on steps 1–3
of the stepwise approach to asthma control, indicating well-
controlled asthma using either reliever medication (short-acting
β2-agonsit) alone or in combination with controller medication
(low-dose inhaled corticosteroid and/or long-acting β2-agonist
(26)
(Table 1). Inclusion criteria for the control group were: a baseline
FEV1 >65% of predicted and a <10% fall in FEV1 following initial
EVH screening. Participants avoided exercise for 24h before
an EVH test, and the HIB group ceased their medication as
previously described(21,24). On EVH test days, participants
abstained from caffeine and alcohol and arrived at the laboratory
>2h post-prandial(27,28). Participants were instructed to abstain
from consumption of n-3 PUFA supplements and eat no more
than two oily ﬁsh meals per week for 3 weeks before the study
and throughout the study(11). Participants were free from acute
upper respiratory tract infections throughout the study.
Experimental design and protocol
This study was conducted in accordance with the Declaration of
Helsinki and all procedures were approved by the Nottingham
Trent University Human Ethics Committee (approval no. 186;
Clinical trial no. ISRCTN80857707). The study adopted a
counter balanced, double-blind, placebo-controlled crossover
design over 14 consecutive weeks (Fig. 1).
Participants were randomised (block randomisation) to
receive three 21 d treatments each separated by a 14-d washout
period. All treatments involved daily oral consumption of eight
capsules (Croda International Plc). Four capsules were taken in
the morning and four in the afternoon with a recommendation
to take with food. The three treatments were: 6·2 g/d n-3 PUFA
(3·7 g EPA and 2·5 g DHA), 3·1 g/d n-3 PUFA (1·8 g EPA and
1·3 g DHA) (INCROMEGATM TG4030; Croda International Plc)
and placebo (CRODAMOLTM GTCC medium chain TAG; Croda
International Plc) (Table 2). CRODAMOLTM GTCC was chosen
as it is readily oxidised in the liver so has little impact on human
health-related biomarkers(29,30). Measurements were taken at
days 0 and 21 of each treatment period. The 6·2 g/d n-3 PUFA
dose was comprised of four n-3 PUFA capsules in the morning
and four n-3 PUFA capsules in the afternoon. To ensure an
equal number of capsules were taken the 3·1 g/d n-3 PUFA
comprised of two n-3 PUFA capsules and two placebo capsules
in the morning and two n-3 PUFA capsules and two placebo
capsules in the afternoon. All capsules (placebo and n-3 PUFA)
were identical in appearance.
Measurement of pulmonary function, eucapnic voluntary
hyperpnoea and fraction of exhaled nitric oxide
The EVH test was undertaken at days 0 and 21 of each treatment
and comprised 6min of breathing dry gas at a target minute
ventilation ( _VE ) of 85% of the predicted maximal voluntary
ventilation (MVV) (30×baseline FEV1). Pulmonary function
(forced vital capacity (FVC), FEV1, peak expiratory ﬂow (PEF)
and forced expiratory ﬂow 25–75% (FEF25–75%)) was assessed
according to ATS/ERS guidelines(31) in triplicate at baseline
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and in duplicate at 3, 6, 16, 20 and 30min after EVH, as
previously described. The highest values recorded were used for
analyses. Baseline FENO was measured (NIOX MINO; Aerocrine)
according to ATS/ERS guidelines(32) in the HIB group only, as it is
elevated in asthma patients but not in healthy controls(33).
Urinary 9α, 11β-PGF2 analysis
Participants provided a urine sample at baseline and at 12, 60
and 90min after EVH. Urinary concentration of 9α, 11β-PGF2,
a metabolite of PGD2, was subsequently determined by ELISA
(Caymen Chemicals) and standardised for urinary creatinine
concentration (ABX Pentra 400; Horiba) based on a kinetic
method using alkaline picrate (Jaffe method)(34). The corrected
9α, 11β-PGF2 was expressed as ng/mmol creatinine. The inter-
and intra-assay CV was <15%. Two control participants and
one HIB participant had samples at day 0 below the limit
of detection for urinary 9α, 11β-PGF2 (5 pg/ml) and were
subsequently excluded from analysis.
Neutrophil phospholipid fatty acid analysis
The neutrophil phospholipid fatty acid composition was
assessed as a measure of compliance to the treatments in
addition to count of capsules returned after each treatment.
Neutrophil cells were isolated from 20ml of whole venous
blood (drawn at baseline from an antecubital vein) through a
three-step puriﬁcation protocol that consisted of dextran
sedimentation (Fisher Scientiﬁc), hypotonic lysis and Ficoll–
Paque sedimentation (GE Healthcare)(35). This method
achieved up to 98% of pure neutrophils which were stored at
−80°C under N until extraction of phospholipids using pre-
viously described methods(36). Fatty acid composition was
analysed by GC as previously described(37). To identify the fatty
acid methyl esters (FAME), retention times were compared
against known standards, Supelco 37 component FAME mix
and PUFA-3 menhaden oil (Sigma). EPA, DHA, arachidonic
acid and linoleic acid were expressed as a percentage of total
fatty acids.
Statistical analysis
The average minimum perceptible improvement in FEV1 in
adults with asthma is 230ml(38), whereas the within participant
SD for the fall in FEV1 after EVH is 100ml
(21). A priori sample
size calculation revealed that with power= 0·90 and α= 0·05,
a sample size of seven in the HIB group would be required to
detect a 230ml improvement in the fall in FEV1 after EVH.
Data were analysed using SPSS. Following assessment for nor-
mality (Shapiro–Wilk test, skewness and kurtosis), data were
analysed using repeated measures ANOVA and Bonferroni
adjusted paired t tests. Statistical signiﬁcance was set at P<0·05.
Data presented are mean values and standard deviations unless
otherwise stated. Within treatment percentage differences (from
day 0 to day 21) for the fall in FEV1 following EVH were calculated
as: ((% fall day 0−% fall day 21)/% fall day 0)×100. For the HIB
group, the individual percentage protection afforded by the n-3
PUFA treatments compared with placebo was calculated for the
% fall in FEV1 following EVH as: ((% fall day 21 placebo−% fall
day 21 treatment)/% fall day 21 placebo)×100. In the HIB group,
the overall severity of HIB was determined by calculating the AUC
for % fall in FEV1 after EVH (AUC0–30) using the trapezoidal rule.
Table 1. Individual anthropometric data, baseline pulmonary function and medication
(Individual values; mean values and standard deviations; percentage predicted)
FVC (litres) FEV1 (litres)
Age (years) Height (cm) Body mass (kg) Volume % Volume % Medications
HIB
1 21 177 75 5·54 106 4·54 103 S
2 44 178 87 4·22 94 3·17 87 S, BUD+FORM
3 21 173 58 3·78 76 2·77 65 S, BUD+FORM
4 38 180 77 4·62 95 3·80 95 S
5 38 173 83 4·43 91 3·49 90 S
6 28 177 68 4·91 96 4·31 100 S
7 22 181 82 5·70 107 5·10 114 S
8 31 173 75 4·10 91 2·84 76 S, BEC
Mean 30 177 76 4·66 95 3·75* 91
SD 9 3 9 0·68 10 0·84 16
Control
1 30 183 80 5·30 98 4·15 92
2 20 184 80 5·93 106 5·18 110
3 20 178 69 4·61 88 4·49 101
4 28 170 84 4·87 103 4·18 104
5 26 184 70 5·23 93 4·90 104
6 23 189 92 5·34 91 5·00 102
7 27 177 69 5·31 103 4·45 103
8 27 181 88 5·46 101 4·69 104
Mean 25 181 79 5·26 98 4·63 103
SD 4 6 9 0·39 7 0·38 7
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; HIB, hyperpnoea-induced bronchoconstriction; S, salbutamol; BUD, budesonide; FORM,
formoterol; BEC, beclomethasone.
*Difference between the HIB and control groups (P=0·017).
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Results
Pulmonary function and ventilation rate during eucapnic
voluntary hyperpnoea
Baseline FEV1 was lower in the HIB group (3·75 (SD 0·81) litres)
than the control group (4·63 (SD 0·37) litres) (P= 0·017) and FVC
tended to be lower in the HIB group (4·66 (SD 0·06) litres) than
the control group (5·26 (SD 0·39) litres) (P= 0·051). There were
no within-group differences in FEV1 or FVC measured at day 0
between the three treatments.
As expected, at day 0 there was a greater peak fall in FEV1
after EVH in the HIB group (pooled data: −29 (SD 17)%) than
Enrollment Assessed for eligibility n 22
Randomised n 18
(n 10 HIB, n 8 CTRL)
Excluded asthma participants (n 2)
Not meeting inclusion criteria (n 0)
Declined to participate (n 0)
Other reasons (n 2) – presented with
physician diagnosed asthma but found to
be HIB negative
Excluded controls (n 2)
Not meeting inclusion criteria (n 0)
Declined to participate (n 2)
Allocation
Allocated to placebo (n 6)
Completed intervention (n 6) Completed intervention (n 5)
n 1 HIB withdrew from study (GI distress) Completed intervention (n 6)
Allocated to 6.2 g/d n-3 PUFA (n 6) Allocated to 3.1 g/d n-3 PUFA (n 6)
n 3 HIB
n 3 CTRL
Completed intervention (n 6)
Allocated to 3.1 g/d n-3 PUFA (n 6)
Completed intervention (n 5)
Allocated to 3.1 g/d n-3 PUFA (n 5)
Completed intervention (n 6)
Allocated to 6.2 g/d n-3 PUFA (n 6)
n 2 HIB
n 3 CTRL
Completed intervention (n 5)
Allocated to placebo (n 5)
Completed intervention (n 5)
Allocated to placebo (n 5)
Completed intervention (n 5)
n 1 HIB withdrew from study (GI distress)
Allocated to 6.2 g/d n-3 PUFA (n 6)
14-d washout period
14-d washout period
Analysis
Analysed
n 8 EIB
n 8 CTRL
Excluded from analysis n 0
• n 12 physician diagnosed asthma
• n 10 controls
• n 3 HIB
• n 3 CTRL
• n 3 HIB
• n 3 CTRL
• n 4 HIB
• n 2 CTRL
• n 4 HIB
• n 2 CTRL
•
•
•
•
• n 3 HIB
• n 3 CTRL
• n 2 HIB
• n 3 CTRL
• n 3 HIB
• n 2 CTRL
Fig. 1. Participant flow diagram. HIB, hyperpnoea-induced bronchoconstriction; CTRL, controls; GI, gastrointestinal.
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the control group (pooled data: −3 (SD 2)%) (P= 0·001). In the
control group, there was no effect of treatment or day on the
peak fall in FEV1 after EVH. In the HIB group, there was a
treatment×day interaction for the peak fall in FEV1 after EVH
(P= 0·011). Further analyses revealed an effect of treatment for
the peak fall in FEV1 after EVH at day 21 (P= 0·001). Speciﬁcally,
the peak fall in FEV1 after EVH was reduced by 34 (SD 14)%
(−690 (SD 460)ml) after 6·2 g/d n-3 PUFA (mean difference= 310
(SD 150)ml, 95% CI 185, 432ml, P= 0·001, effect size= 0·70), and
by 30 (SD 11)% (−700 (SD 420)ml) after 3·1 g/d n-3 PUFA (mean
difference= 270 (SD 120)ml, 95% CI 170, 377ml, P= 0·001, effect
size= 0·58). The reduced peak falls in FEV1 after 6·2 and 3·1 g/d
n-3 PUFA were not different (P= 0·834) (Fig. 2, Table 3).
The percentage protection afforded by the n-3 PUFA treatments
compared with placebo is shown in Table 3. The peak fall in
FEV1 was unchanged from day 0 to day 21 of placebo.
Fig. 3 shows the percentage change in FEV1 during 30min
recovery after EVH in the HIB group. At day 0, the percentage
change in FEV1 during recovery was not different between
treatments. At day 21, the percentage change in FEV1 was
reduced for up to 20 and 30min recovery after 6·2 and 3·1 g/d
n-3 PUFA, respectively. Furthermore, compared with placebo
at day 21, the percentage change in FEV1 was lower for up to
6 and 20min recovery after 6·2 and 3·1 g/d n-3 PUFA,
respectively.
In the HIB group, there was a treatment× day interaction for
AUC0–30 (P= 0·004). Further analysis revealed that at day 21 the
AUC0–30 was reduced after 6·2 g/d (−415 (SD 382), P= 0·002)
and 3·1 g/d (−398 (SD 399), P= 0·001) n-3 PUFA compared with
placebo (−595 (SD 424)). The AUC0–30 at day 21 of 6·2 and
3·1 g/d n-3 PUFA was not different (P= 0·751).
Consistent with our previous ﬁndings(21,39) the peak fall in
FEV1 after EVH in the HIB group was reproducible with no
differences occurring between day 0 of the three treatments
(within participant CV= 7 (SD 4)%; measurement error= 84ml;
reproducibility= 231ml; smallest meaningful change= 115ml).
The peak fall in FVC showed similar outcomes. At day 0 of the
three treatments the peak fall in FVC was greater in the HIB
group (pooled data: −992 (SD 604)ml; −21 (SD 15)%) than the
control group (pooled data: −140 (SD 90)ml; −3 (SD 2)%)
(P= 0·004). In the control group, the peak fall in FVC was
unchanged after placebo and both doses of n-3 PUFA. The
peak fall in FVC after EVH at day 0 was reduced by 30 (SD 21)%
after 6·2 g/d n-3 PUFA and by 29 (SD 24)% after 3·1 g/d n-3
PUFA but was unchanged after placebo in the HIB group. The
reduced peak fall in FVC after 6·2 and 3·1 g/d n-3 PUFA was not
different (P= 0·847). In the HIB group, the peak fall in PEF was
unchanged after placebo and both n-3 PUFA treatments
(pooled data: −2·52 (SD 1·68) litre/s). In the HIB group, the peak
fall in FEF25–75% was reduced from day 0 (−1·55 (SD 0·37) litre/s)
to day 21 (−1·24 (SD 0·45) litre/s) of 6·2 g/d n-3 PUFA (mean
difference= 0·31 (SD 0·23) litre/s, 95% CI 0·12, 0·50 litre/s,
P= 0·006, effect size= 0·77). In the HIB group, the peak fall
in FEF25–75% was unchanged after 3·1 g/d n-3 PUFA and
placebo in the HIB group, and after all treatments in the
control group (P> 0·05).
Minute ventilation achieved during each of the six
EVH trials did not differ in the HIB group (P> 0·05; between
trial CV= 0·23) (pooled data: 109·5 (SD 21·4) litre/min;
78 (SD 18)% of MVV target) which was less compared
with the control group (P= 0·001; between trial CV= 0·09)
(pooled data: 133·4 (SD 10·8) litre/min; 60 (SD 6)% of MVV
target).
Fraction of exhaled nitric oxide
In the HIB group, there was a treatment× day interaction for
FENO (P= 0·004). After 6·2 g/d n-3 PUFA, FENO was reduced
by 24% from day 0 (48 (SD 33) parts per billion (ppb)) to day 21
(35 (SD 28) ppb) (mean difference= 13 (SD 12) ppb, 95% CI 3,
24 ppb, P= 0·020, effect size= 0·41). Similarly, after 3·1 g/d n-3
PUFA, FENO was reduced by 31% from day 0 (49 (SD 33) ppb)
to day 21 (34 (SD 28) ppb) (mean difference= 15 (SD 14) ppb,
95% CI 4, 27 ppb, P= 0·018, effect size= 0·46) (Fig. 4). The
reduced FENO after 6·2 and 3·1 g/d n-3 PUFA was not different
(P= 0·491) (Fig. 4). FENO remained unchanged from day 0
(47 (SD 26) ppb) to day 21 (47 (SD 27) ppb) of placebo.
Urinary 9α, 11β PGF2
Baseline urinary 9α, 11β PGF2 did not differ between the
HIB group (day 0 pooled data: 40·85 (SD 21·49) ng/mmol
Table 2. Fatty acid composition (% total fatty acids) of the n-3 PUFA (INCROMEGATM TG4030) and placebo (CRODAMOLTM GTCC,
medium-chain TAG) treatments*
% Total fatty acids
Fatty acids Name n-3 PUFA (INCROMEGA™ TG4030) Placebo (CRODAMOLTM GTCC)
8 : 0 Caprylic acid 56
10 : 0 Capric acid 43
18 : 4 n-3 Octadecatetraenoic acid 3
20 : 4 n-6 Arachidonic acid 3
20 : 4 n-3 Eicosatetraenoic acid 2
20 : 5 n-3 Eicosapentaenoic acid 45
21 : 5 n-3 Heneicosapentaenoic acid 2
22 : 5 n-3 Docosapentaenoic acid 6
22 : 6 n-3 Docosahexaenoic acid 31
Total 92 99
* Individual fatty acids making up ≥1% are shown.
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creatinine) and the control group (day 0 pooled data: 27·05
(SD 14·01) ng/mmol creatinine) (P= 0·133). There were no
within-group differences in urinary 9α, 11β PGF2 measured
before EVH at days 0 and 21 of the three treatments.
At day 0, urinary 9α, 11β PGF2 increased by 31·53
(SD 22·77) ng/mmol creatinine (pooled data) after EVH in the
HIB group (P= 0·030) but not in the control group (pooled
data: 11·11 (SD 16·30) ng/mmol creatinine). At day 0, changes in
9α, 11β PGF2 after EVH were different between groups
(P= 0·003). In the HIB group, subsequent analyses revealed an
effect of treatment on the peak increase in 9α, 11β PGF2 after
EVH at day 21 (P= 0·014). Speciﬁcally, the peak increase in 9α,
11β PGF2 after EVH was reduced after 6·2 g/d n-3 PUFA (mean
difference= 11·75 (SD 7·42) ng/mmol creatinine, 95% CI 5·54,
17·96 ng/mmol creatinine, P= 0·009, effect size= 0·50) and
3·1 g/d n-3 PUFA (mean difference= 12·86 (SD 14·90) ng/mmol
creatinine, 95% CI 0·40, 25·33 ng/mmol creatinine, P= 0·041,
effect size= 0·40). The reduced peak increase in 9α, 11β PGF2
after EVH following 6·2 and 3·1 g/d n-3 PUFA was not different
(P= 0·377) (Fig. 5). There was no effect of placebo on the
increase in urinary 9α, 11β PGF2 after EVH.
Compliance assessment – neutrophil phospholipid fatty
acid content, and capsule counts
Good compliance to all treatments was shown from the capsule
counts in both the HIB and control groups (Table 4). Further
compliance evidence was provided from the neutrophil phos-
pholipid fatty acid content. In the HIB group, 6·2 g/d n-3 PUFA
increased EPA (P= 0·002) and DHA (P= 0·045) content, and
reduced arachidonic acid (P= 0·005). In the HIB group, 3·1 g/d
n-3 PUFA increased EPA content (P= 0·018) and reduced ara-
chidonic acid (P= 0·009); there was a trend for an increase in
DHA content (P= 0·074). In the HIB group, linoleic acid content
was unchanged after 6·2 and 3·1 g/d n-3 PUFA. Phospholipid
fatty acid content was unchanged after placebo in both groups.
In the control group, 6·2 g/d n-3 PUFA tended to increase EPA
(P= 0·054) and DHA content (P= 0·087), whereas 3·1 g/d n-3
PUFA increased DHA content (P= 0·007) and reduced arachi-
donic acid (P= 0·038); EPA content was unchanged (Table 4).
Discussion
Previous research has shown that high doses of n-3 PUFA
(5·2–5·4 g/d) reduce the severity of HIB and EIB(10,11,15–17). The
present study demonstrates that a lower dose of 3·1 g/d n-3
PUFA is equally effective in reducing HIB in adult men with
asthma. The 6·2 and 3·1 g/d n-3 PUFA treatments also resulted
in similar reductions in baseline FENO, and comparable sup-
pression of urinary 9α, 11β-PGF2 after EVH. These ﬁndings
suggest that 3·1 g/d n-3 PUFA could be used as an adjunct
therapy for physically active adults with asthma and EIB. The
percentage protection afforded by 6·2 g/d n-3 PUFA (35
(SD 14)%) and 3·1 g/d n-3 PUFA (33 (SD 12)%) highlights the
efﬁcacy of n-3 PUFA as an adjunct therapy. The percentage
protection afforded by n-3 PUFA is comparable with montelukast
(50mg twice daily)(40) but less than the 60–70% protection
afforded by short-acting β2-agonists procaterol (10 micrograms/
inhalation) and albuterol (90 micrograms/inhalation)(41). Long-
acting β2-agonists also provide effective treatment for EIB
(42–44),
although chronic treatment with both long- and short-acting
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Fig. 2. Peak falls in forced expiratory volume in 1 s (FEV1) before and after
placebo (a), 6·2g/d n-3 PUFA (b), and 3·1 g/d n-3 PUFA (c) in the hyperpnoea-
induced bronchoconstriction (HIB) group (n 8). Values are means, and
standard deviations represented by vertical bars and identical symbols
represent the same HIB participant. * Day 0 v. day 21 (P=0·001).
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β2-agonists can result in tolerance
(45,46). Furthermore, compliance
to the lower 3·1g/d n-3 PUFA dose may be improved due to
reduced capsule numbers, reduce cost and risk of gastrointestinal
distress, which is commonly associated with bloating, and
stomach upset. Indeed, two participants withdrew from the study
when on the 6·2g/d n-3 PUFA treatment due to gastrointestinal
distress, whereas full compliance and no participant withdrawals
(capsule counts) was observed with 3·1 g/d n-3 PUFA.
The EVH test is an indirect bronchial provocation test that is a
suitable objective surrogate for identifying EIB(24). We have
previously reported that the EVH protocol used in the present
study elicits a highly reproducible fall in FEV1
(21,39) which is
crucial when assessing treatment efﬁcacy. The approximately
290ml (32%) decrease in the post-EVH fall in FEV1 after 6·2
and 3·1 g/d n-3 PUFA supplementation exceeds the minimum
perceptible change of 230ml(38) and is therefore clinically
relevant. Our ﬁndings are in agreement with previous studies
showing an attenuation of HIB(17) and EIB(11) after n-3 PUFA
supplementation in adults with asthma. These ﬁndings collec-
tively support the ATS/ERS guidance(25) suggesting n-3 PUFA
supplementation could be of beneﬁt in individuals with EIB. Our
ﬁndings are also in broad agreement with work on n-3 PUFA
supplementation in elite athletes with EIB(10), and asthmatic
patients with EIB and HIB(11,15–17). An interesting difference is
that previous work showed abolition of EIB after n-3 PUFA
supplementation(10), whereas in the present study only three
participants became non-diagnostic (Fig. 2). This may be partly
due to inter-study differences in the severity of EIB: the peak fall
in FEV1 in the present study (−30%) was approximately 50%
greater than that reported in previous n-3 PUFA supplementation
studies demonstrating a reduction in EIB/HIB(11,15–17).
Unlike the rather consistent ﬁnding that pharmacological
therapy reduces EIB(42–44), the efﬁcacy of n-3 PUFA remains
controversial. Our ﬁndings contrast those of Arm et al.(9) and
Brannan et al.(12) who despite using relatively high n-3 PUFA
doses (5·4–6·0 g/d), reported no change in bronchial hyperre-
sponsiveness to inhaled histamine and mannitol, respectively.
Arm et al.(9) reported no change in airway resistance (fall in FEV1
was not measured) after a cycling exercise challenge, although
their data are confounded by: (1) the suggestion that low-grade,
non-pharmaceutical n-3 PUFA was used(47); (2) low statistical
power due to the small number of participants (n 6) performing
the exercise; (3) exercise being performed at ambient tempera-
ture and humidity, which may result in insufﬁcient environmental
stress; and (4) the low exercise intensity (60–130W) which
likely (data not measured/reported) elicited only a modest
increase in _VE . The efﬁcacy of n-3 PUFA supplementation may
also partly depend on the choice of bronchial provocation test.
Direct bronchial provocation tests such as inhaled histamine act
directly on receptors on the airway smooth muscle causing
contraction(48) and may not, therefore, fully reveal the potential
anti-inﬂammatory effects of n-3 PUFA. Indirect bronchial
provocation tests such as mannitol and EVH both alter the
tonicity and volume of the airway surface liquid thereby
Table 3. Individual peak % fall in forced expiratory volume in 1 s (FEV1) at days 0 and 21 of each treatment and percentage protection
afforded by n-3 PUFA in the hyperpnoea-induced bronchoconstriction (HIB) group
Peak % fall in FEV1
Percentage protection afforded by n-3 PUFA
Placebo 6·2 g/d n-3 PUFA 3·1 g/d n-3 PUFA treatments for peak % fall in FEV1*
HIB Day 0 Day 21 Day 0 Day 21 Day 0 Day 21 6·2 g/d n-3 PUFA 3·1g/d n-3 PUFA
1 −12·58 −13·10 −13·02 −6·54 −14·95 −9·98 50 24
2 −63·22 −64·81 −61·04 −51·36 −60·32 −49·84 21 23
3 −48·73 −47·40 −48·20 −33·70 −48·92 −32·83 29 31
4 −32·90 −28·10 −28·50 −19·54 −30·45 −22·91 30 18
5 −27·02 −32·64 −29·71 −14·98 −26·44 −23·12 54 29
6 −19·72 −18·01 −17·33 −11·67 −18·41 −10·50 35 42
7 −17·74 −16·21 −16·05 −8·64 −13·04 −8·63 47 47
8 −14·83 −15·82 −15·71 −13·67 −13·78 −7·90 14 50
Mean −30 −30 −29 −20 −28 −21 35 33
SD 18 18 17 15 18 15 14 12
* Percentage protection afforded by the n-3 PUFA treatments calculated as: ((% fall day 21 placebo−% fall day 21 treatment)/% fall day 21 placebo) × 100.
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Fig. 3. Percentage change in forced expiratory volume in 1 s (FEV1) after
eucapnic voluntary hyperpnoea (EVH) in participants with hyperpnoea-induced
bronchoconstriction (HIB). A 10% fall in FEV1 (shown by the ) is
diagnostic of HIB. , Day 0 of placebo treatment; , day 21 of placebo
treatment; , day 0 of 6·2 g/d n-3 PUFA treatment; , day 21 of 6·2 g/d n-3
PUFA; , day 0 of 3·1g/d n-3 PUFA; , day 21 of 3·1g/d n-3 PUFA.
Mean values with unlike letters were significantly different: a, 6·2g/d n-3 PUFA
v. placebo; b, 3·1 g/d n-3 PUFA v. placebo; c, day 0 v. day 21 of 6·2g/d n-3
PUFA; d, day 0 v. day 21 of 3·1g/d n-3 PUFA. P< 0·05, * P< 0·01, ** P< 0·001.
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promoting the release of bronchoconstrictive inﬂammatory
mediators(49,50). However, mannitol and EVH may exert differ-
ent levels of osmotic and mechanical stress on the airways.
Speciﬁcally, mannitol induces dehydration stress primarily in
the proximal airways(50,51), whereas the high _VE during EVH
results in the dehydration stress being extended to peripheral
airways(52) which are increasingly recruited to heat and humi-
dify inspired air. Furthermore, EVH also elicits airﬂow-induced
shear stress and high transepithelial pressure gradients(53).
These differences may predispose the airway epithelium to
greater damage after EVH than mannitol; indeed, EVH tends to
result in greater increases in urinary Clara cell protein 16 con-
centration, a marker of airway epithelial damage(54,55). This is
signiﬁcant because n-3 PUFA supplementation attenuates the
increase in urinary Clara cell protein concentration after EVH,
which suggests that reduced HIB may be partly due to reduced
airway epithelial damage(56). Differences in the intensity of the
stimulus to the airways may thus explain the divergent effects of
n-3 PUFA supplementation on bronchial hyperresponsiveness
to EVH and mannitol.
Recently, Price et al.(18) reported no change in the severity
of HIB or markers of airway inﬂammation (FENO, urinary 9α,
11β PGF2 and cysteinyl leukotriene E4) in recreationally active
adults supplemented daily with a combined treatment of
30 µg vitamin D3 with n-3 PUFA (3·0 g EPA and 2·0 g DHA).
Unfortunately, objective treatment compliance measures
(e.g. neutrophil phospholipid DHA and EPA content) were not
taken in this study. The fall in FEV1 after EVH was also modest
(approximately 16%) compared with the approximately 30%
fall observed at day 0 in the present study, and six from ten of
the participants did not have physician diagnosed asthma (and
consequently no asthma medication). Two participants in Price
et al.(18) also became non-diagnostic for HIB after the placebo
treatment. It may be that n-3 PUFA supplementation is thus
more effective in individuals with diagnosed asthma and more
severe HIB, as observed in the present study.
The increase in urinary 9α, 11β-PGF2 after EVH at day 0 in the
HIB group is similar in magnitude to that reported previously
in adults with asthma performing exercise or EVH(10,57). The
reduced increase in 9α, 11β-PGF2 after EVH was comparable
after 6·2 and 3·1 g/d n-3 PUFA supplementation. Previous
work also reports a reduced increase in 9α, 11β-PGF2 after
EVH following n-3 PUFA supplementation(10). The increased
EPA and DHA cell membrane content following n-3 PUFA
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Fig. 4. Baseline fraction of exhaled nitric oxide (FENO) before and after
placebo (a), 6·2 g/d n-3 PUFA (b) and 3·1g/d n-3 PUFA (c) in the hyperpnoea-
induced bronchoconstriction (HIB) group (n 8). Values are means, and
standard deviations represented by vertical bars and identical symbols
represent the same HIB participant. * Day 0 v. day 21 (P< 0·05) ppb, Parts
per billion.
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supplementation is likely to result in dual inhibition of
arachidonic acid-dependent cyclo-oxygenase and 5-lipoxygenase
pathways which are responsible for eicosanoid generation(7).
This may explain the decrease in 9α, 11β-PGF2, a metabolite of
the arachidonic acid-derived pro-inﬂammatory eicosanoid
PGD2. The osmotic changes in the airways following EVH
results in mast cell activation and release of PGD2 during
bronchoconstriction(49,50). Suppression of mast cell activation, and
reduced eicosanoid generation, may thus partially explain reduced
HIB after n-3 PUFA supplementation.
The comparable reduction in baseline FENO after 6·2 and
3·1 g/d n-3 PUFA supplementation concurs with previous
work(17,58) and is indicative of reduced baseline eosinophilic
airway inﬂammation. Increased FENO can also result from
elevated expression of inducible nitric oxide synthase in T-cells,
macrophages, airway epithelial cells, and other inﬂammatory
cells within the airways(59,60). Elevated expression of inducible
nitric oxide synthase can be induced by certain pro-inﬂammatory
cytokines such as TNF-α(59,60) probably via the activation of
NF-κB transcription factor(61). The n-3 and n-6 PUFA modulate
NF-κB transcription factor activation(62) and presumably therefore
TNF-α expression, which may explain the observed fall in FENO
after n-3 PUFA supplementation in the present study. Support for
this argument comes from work showing that 5·4 g/d n-3 PUFA
suppresses circulating plasma TNF-α in athletes with EIB(10). The
comparable reduction in both baseline FENO and the post-EVH
increase in 9α, 11β-PGF2 after 6·2 and 3·1 g/d n-3 PUFA
supplementation suggests that both doses increased the n-3
PUFA content of the phospholipid bilayer of cell membranes
to inﬂuence the inﬂammatory response. Furthermore, and con-
sistent with previous reports(17,56), the lower FENO observed after
n-3 PUFA supplementation in the present study may have
resulted from an increase in airway pH, which is considered a
determinant of FENO and airway inﬂammation
(63).
Limitations of the current study include no run-in period to
assess habitual n-3 PUFA intake, the exclusion of females, the
comparatively low participant numbers, and the wide range of
asthma phenotypes suggested by the heterogeneous fall in
FEV1 and large variation in inﬂammatory markers after EVH.
However, our cohort provides evidence for the use of n-3 PUFA
in more severe HIB than previous literature(10,11). Future work
may explore whether particular asthma phenotypes and
HIB/EIB severity respond preferentially to n-3 PUFA supple-
mentation. Furthermore, given the existing inter-study differ-
ences regarding the efﬁcacy of n-3 PUFA for the management
of EIB, further studies using larger sample sizes are warranted.
In conclusion, 3·1 g/d n-3 PUFA supplementation effectively
reduced HIB in men with asthma to a similar extent as a higher
dose. Lower doses of n-3 PUFA thus represent a potentially
beneﬁcial adjunct treatment for adults with asthma and EIB,
whilst also reducing the burden of cost, compliance and
potential gastrointestinal distress. Further studies are needed to
elucidate if the bronchial provocation test used and the severity
of asthma and HIB/EIB affect the degree of protection afforded
by n-3 PUFA supplementation.
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